Breakwater Capital Group Sells 131 Shares of Danaher Co. (NYSE:DHR)

Breakwater Capital Group trimmed its stake in shares of Danaher Co. (NYSE:DHR) by 4.4% during the fourth quarter, Holdings Channel reports. The firm owned 2,822 shares of the conglomerate’s stock after selling 131 shares during the period. Breakwater Capital Group’s holdings in Danaher were worth $648,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. FMR LLC grew its stake in Danaher by 15.8% during the third quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after buying an additional 3,217,631 shares during the last quarter. Legal & General Group Plc grew its position in shares of Danaher by 2.4% during the 2nd quarter. Legal & General Group Plc now owns 5,964,031 shares of the conglomerate’s stock worth $1,490,112,000 after buying an additional 139,989 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Danaher by 3.0% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,097,986 shares of the conglomerate’s stock valued at $1,417,342,000 after acquiring an additional 148,251 shares during the last quarter. Fisher Asset Management LLC increased its stake in shares of Danaher by 2.6% in the 3rd quarter. Fisher Asset Management LLC now owns 4,552,640 shares of the conglomerate’s stock valued at $1,265,725,000 after acquiring an additional 116,299 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA increased its holdings in shares of Danaher by 17.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock worth $996,141,000 after acquiring an additional 535,254 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors.

Danaher Stock Performance

Shares of DHR opened at $239.83 on Tuesday. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The stock has a 50-day moving average price of $235.52 and a 200-day moving average price of $253.65. The company has a market cap of $173.22 billion, a PE ratio of 45.77, a price-to-earnings-growth ratio of 4.32 and a beta of 0.83. Danaher Co. has a 12-month low of $222.53 and a 12-month high of $281.70.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The business had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.59 billion. During the same quarter in the prior year, the firm earned $2.02 earnings per share. The firm’s revenue was up 3.1% on a year-over-year basis. As a group, equities analysts forecast that Danaher Co. will post 7.5 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be issued a $0.27 dividend. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.45%. Danaher’s payout ratio is 20.61%.

Analyst Upgrades and Downgrades

DHR has been the topic of several recent research reports. Wolfe Research raised Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price target on the stock in a research note on Thursday, October 31st. Royal Bank of Canada lowered their price objective on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. TD Cowen raised their price target on Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a report on Wednesday, October 23rd. UBS Group lowered their target price on Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a research note on Wednesday, October 23rd. Finally, Robert W. Baird lowered their target price on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Six investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $286.80.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.